Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion type Assertion NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_head.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion description "[We have compared the kinetics of minimal residual disease (MRD) by simultaneous polymerase chain reaction (PCR) monitoring with oligonucleotides for the immunoglobulin heavy chain (IgH) complementarity-determining region 3 (CDR3) and the T-cell receptor gamma chain gene (TCR gamma), as well as clone-specific CDR3 sequences in adult patients (aged 17-51 years) with acute lymphoblastic leukemia (ALL) who entered a complete hematological remission (CR) after chemotherapy with the German multicenter ALL (GMALL) protocol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_provenance.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion evidence source_evidence_literature NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_provenance.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion SIO_000772 7578520 NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_provenance.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion wasDerivedFrom befree-20150227 NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_provenance.
- NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_assertion wasGeneratedBy ECO_0000203 NP791339.RA_DKz4H7-f2M9A3tHu_Q06f3Xfiqs3Y7OYVvilHuxrJs130_provenance.